Novavax To Produce 2 Bn Doses of COVID Vaccine With New India Deal

Novavax had earlier signed a deal with SII to produce a minimum of one billion doses of its vaccine candidate.

Published
Treatment & Vaccine
1 min read
US vaccine developer Novavax on Tuesday said that it planned to double it manufacturing capacity for the COVID-19 vaccine.
i

US vaccine developer Novavax on Tuesday, 15 September, said that it planned to double its manufacturing capacity for the COVID-19 vaccine. According to a Reuters report, it seeks to produce two billion doses of the vaccine annually under an agreement with the Serum Institute of India (SII).

Novavax had earlier signed a deal with SII to produce a minimum of one billion doses of its vaccine candidate, NVX-CoV2373, for India as well as other low- and middle-income countries.

As per the new agreement, SII will also produce the antigen component of the vaccine. This will bring Novavax’s manufacturing capacity to over two billion doses by mid-2021.

Novavax’s vaccine candidate is currently in mid-stage trials. A study conducted for the vaccine at an early stage indicated that it induced the production of high levels of antibodies against COVID-19. The pharmaceutical company hopes to begin late-stage trials in the third quarter.

Last month, Novavax promised to supply 60 million doses of its COVID-19 vaccine candidate to the UK by the first quarter of 2021.

It also plans to provide 100 million doses of the vaccine to the United States by January, and has signed agreements with Japan and Canada.

(With inputs from Reuters)

(Make sure you don't miss fresh news updates from us. Click here to stay updated)

Stay Up On Your Health

Subscribe To Our Daily Newsletter Now.

Join over 120,000 subscribers!